NT5E and pancreatic ductal adenocarcinoma: Coupling RFA with immune checkpoint inhibitors and adenosine-CD73 blockade offers a promising strategy to overcome the intrinsic immune resistance of pancreatic ductal adenocarcinoma (PDAC).